title: [Neuroleptic drug utilization among schizophrenic outpatients].
abstract: BACKGROUND
  Our objective was to describe and compare neuroleptic drug utilization patterns among French schizophrenic outpatients in public and private care settings.
  
  
  METHODS
  A cross sectional survey was carried out by a random sample of 61 public and 112 private psychiatrists who registered for one month all schizophrenic adult outpatients treated with a neuroleptic drug. Among registered patients, each psychiatrist was to include a maximum of 18 patients (public setting) or 9 patients (private setting). Statistical analysis was weighted to take into account for psychiatrist activity level, assessed by patient registration.
  
  
  RESULTS
  Psychiatrists included 934 patients in the public care setting and 927 patients in the private care setting. Patients were (mean+/-sd) 40.1+/-12.1 years old, 60.9% men. The patients' social and clinical characteristics were less favorable in the public setting than in the private setting: no professional activity (78.9% vs 65.1%), living in institution (7.2% vs 3.7%), under legal protection (35.1% vs 14.5%), drug abuse (9.6% vs 5.6%). An atypical neuroleptic was prescribed for 63.0% of patients and a classic neuroleptic for 49.7%, an association of neuroleptics for 22.0%. In both settings, the most prescribed neuroleptics were olanzapine (28.0%) and risperidone (18.6%) with a higher mean daily dosage in the public care setting. At least one neuroleptic treatment change (drug and/or dosage) occurred during the previous year for 44.9% and 39.2% patients, in public and private settings, respectively. In both settings, reasons for changes were mainly lack of efficacy (55.1%) and side effects (49.8%).
  
  
  CONCLUSIONS
  Public and private care populations were different but not as much as expected. In both settings, atypical neuroleptics were the predominant drugs used in the treatment of schizophrenia outpatients. The high frequency of drug change for lack of efficacy or side effects demonstrates the difficulties with the use of the present neuroleptic armamentarium.
authors.affiliation: Département de Pharmacologie, Université Victor-Segalen/Bordeaux 2, Carreire zone Nord, case 36, 33076 Bordeaux Cedex. patrick.blin@pharmaco.u-bordeaux2.fr
authors.forename: P
authors.initials: P
authors.lastname: Blin
authors.forename: J-P
authors.initials: JP
authors.lastname: Olié
authors.forename: D
authors.initials: D
authors.lastname: Sechter
authors.forename: F
authors.initials: F
authors.lastname: Petitjean
authors.forename: P
authors.initials: P
authors.lastname: Cialdella
authors.forename: A
authors.initials: A
authors.lastname: Gérard
authors.forename: L
authors.initials: L
authors.lastname: Hanssens
authors.forename: J
authors.initials: J
authors.lastname: Westerloppe
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care / Q000706:statistics & numerical data*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D004359:Drug Therapy, Combination; D004363:Drug Utilization; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine